Business Wire Feed
Akamis Bio Announces Encouraging Preliminary Results from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer
NG-350A combined with chemoradiotherapy demonstrated promising efficacy and a favorable safety profile Composite response rate of 50 percent observed across the first 10 patients who completed the active treatment period, with no serious adverse events more...
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection
The NEU-002 program extends the ELANE pathway into systemic delivery, building on a cancer-selective mechanism that kills tumor cells while sparing immune cells and activating anti-tumor immunity. NEU-002 program leads demonstrated anti-tumor activity following intravenous more...
Weave’s Latest Platform Enhancements Power Smarter Growth for Healthcare Practices
AI-powered innovations reinforce Weave’s position as the leading healthcare software platform for patient experience and practice performanceLEHI, Utah--(BUSINESS WIRE)--#getweave--Weave (NYSE: WEAV), a leading AI-powered patient communications and engagement platform purpose-built for healthcare practices, highlights the more...
Ensem Therapeutics Highlights Novel, Potent, and Selective Oral pan-KRAS and WRN Inhibitors with Best-in-Class Potential
Preclinical Data to be Presented at the AACR Annual Meeting Showcasing Ensem’s Advancements in Next-Generation Precision OncologyWALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a clinical-stage, oncology-focused biopharmaceutical company, today announced presentations of preclinical data at the more...
CUPE Ontario’s Health care workers coordinating committee to hold round table discussions at Queen’s Park
Toronto, ON.--(BUSINESS WIRE)--Workers from CUPE Ontario’s Health care workers coordinating committee (HCWCC) will be holding round table discussions with MPPs on Monday, April 20th. The discussions will focus on the challenges facing Long Term Care more...
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
ENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosingRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United more...
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™
ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at IMMUNOLOGY2026, more...
Pulse Biosciences to Host Analyst Event on April 25, 2026
Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter SystemHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced more...
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and more...
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
MUNICH--(BUSINESS WIRE)--$BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR more...
As Clinicians Leave Traditional Medicine to Build a Better Model, Ultralight Raises $9.3M to Power What Comes Next
Ultralight replaces fragmented medical software with a single AI-native system, built for functional, integrative, and longevity practicesSAN FRANCISCO--(BUSINESS WIRE)--Most doctors went into medicine to help people. But the system they entered wasn't built for that more...
Geviti Launches First-to-Market Free, Clinically Backed AI Platform for Health Data Interpretation
The platform is now offering AI as a “force multiplier” to enhance expert-led health analysis across blood biomarkers to all users.PHOENIX--(BUSINESS WIRE)--Geviti Health, a precision health platform focused on preventative care, has announced the launch more...
Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors
Acerand Therapeutics Reports Promising Clinical Activity and Favorable Safety Profile for ACE-106, a Potential Best-in-Class PARP1 Selective InhibitorSHANGHAI & INDIANAPOLIS--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, metabolic diseases, more...
Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails
-Delve Bio to Present Two Oral Presentations at American Academy of Neurology 2026 Annual Meeting-BOSTON--(BUSINESS WIRE)--#biotech--Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical more...
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter more...
Signet Jewelers Raises Record-Breaking $12 Million Benefitting St. Jude Children’s Research Hospital
Donation represents Signet's largest single-year fundraising total Signet’s tradition of supporting the St. Jude mission of helping children with cancer and other life-threatening diseases spans 27 years and more than $122 million raisedAKRON, Ohio--(BUSINESS WIRE)--Signet more...
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, more...
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 more...
Promega to Showcase Oncology Research Tools and Companion Diagnostics at AACR Annual Meeting 2026
Bioluminescence tools, companion diagnostics and automated sample preparation headline Promega presence at AACR 2026MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation, a Madison, Wisconsin-based life science tools company, will present new technologies for cell health, target engagement and oncology more...
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Pathlight™, a personalized, tumor-informed molecular residual disease (MRD) platform, will expand Foundation Medicine’s testing capabilities Pathlight uses a proprietary combination of whole genome sequencing (WGS) and digital PCR to identify and track structural variants (SVs) more...
Registrar Corp Acquires Dell Tech, Expanding Canadian Regulatory Expertise and Strengthening Global Market Access Solutions
HAMPTON, Va.--(BUSINESS WIRE)--#CanadaRegulatoryExpertise--Registrar Corp, the leading provider of regulatory compliance solutions for the food and beverage, medical device, cosmetic, and drug industries and a Paine Schwartz Partners portfolio company, announced its acquisition of Dell Tech, more...
Amazfit Unveils the Cheetah 2 Pro, a Performance Running Watch Built for Marathon Preparation
Titanium design meets structural lightness, engineered for the demands of marathon training cyclesMILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Cheetah 2 Pro, the newest addition to more...
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence that more...
Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ™
New functionality puts the power of lesion-specific plaque analysis directly into the physician’s hands, giving deeper insight into coronary and carotid artery diseaseBOSTON--(BUSINESS WIRE)--#CardiacImaging--Elucid announced today the commercial availability of a new Lesion Inspection Tool more...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment -DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform more...